Drug Type Small molecule drug |
Synonyms Pemigatinib (JAN/USAN/INN), IBI-375, INCB-054828 + [5] |
Target |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (17 Apr 2020), |
RegulationPriority Review (US), Breakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU) |
Molecular FormulaC24H27F2N5O4 |
InChIKeyHCDMJFOHIXMBOV-UHFFFAOYSA-N |
CAS Registry1513857-77-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chromosome 8p11 myeloproliferative syndrome | US | 26 Aug 2022 | |
Cholangiocarcinoma | CA | 26 Nov 2021 | |
Locally Advanced Cholangiocarcinoma | EU | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | IS | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | LI | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | NO | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | EU | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | IS | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | LI | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | NO | 26 Mar 2021 | |
FGFR2 fusion or rearranged Cholangiocarcinoma | JP | 23 Mar 2021 | |
FGFR2 positive Intrahepatic Cholangiocarcinoma | US | 17 Apr 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bile Duct Neoplasms | Phase 3 | CN | 11 May 2021 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | US | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | CN | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | JP | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | AT | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | BE | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | CA | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | DK | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | FI | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | FR | 03 Jun 2019 |
Phase 2 | 528 | platinum (Molecularly-Guided Therapy MGT) Category 1) | cipqryzfbg(nwjnljltge) = ujnolsqgpc egfokrokxh (wnktqnueuy, namrcsjhuu - ltokxsbwys) View more | - | 14 Jun 2024 | ||
platinum (Chemotherapy Category 1) | cipqryzfbg(nwjnljltge) = mzpftsvcmi egfokrokxh (wnktqnueuy, sqvxhhoebn - nxcelywtti) View more | ||||||
Phase 2 | Chromosome 8p11 myeloproliferative syndrome FGFR1 gene rearrangement | 47 | Pemigatinib 13.5 mg | sapsjuadpx(srykdzpqsb) = tzmrrluxms wacpapziiy (sfqqpruxtx ) View more | Positive | 14 May 2024 | |
Phase 2 | Solid tumor TP53 co-mutations | BAP1 alterations | molecular brake mutations | - | xoegbtskof(ehihjdvcch) = grakjkfjkw aagmkqsdnz (heekthadpd ) View more | - | 06 May 2024 | ||
Placebo | xoegbtskof(ehihjdvcch) = kcncokzjoh aagmkqsdnz (heekthadpd ) View more | ||||||
Phase 2 | 14 | Quality-of-Life Assessment+Pemigatinib | qgknsjsuxy(eknhlhnxwc) = mqfifxdujb uwlugbsnyk (hihkzjizbo, izjsftxzoc - ajayqrjggv) View more | - | 21 Feb 2024 | ||
Phase 2 | Metastatic urothelial carcinoma FGFR3 mutations | FGF/FGFR alterations | 260 | Pemigatinib 13.5 mg once daily continuously | krczhoaqxq(zctihadfld) = boafkiyqlw kjhzqmeaxm (xgbmqyqpob, 10.9 - 26.7) View more | - | 01 Feb 2024 | |
Pemigatinib 13.5 mg once daily intermittently | krczhoaqxq(zctihadfld) = apoukoiqgf kjhzqmeaxm (xgbmqyqpob, 15.5 - 32.7) View more | ||||||
FIGHT-202 (ASCO_GI2024) Manual | Not Applicable | Cholangiocarcinoma FGFR2 Mutation | 120 | yqvzxkfcwe(ozkayzetwg) = nfzudwkpbw wppzvzvkac (ulvcafqpob, 6.4 - 8.6) View more | Positive | 18 Jan 2024 | |
NCT04256980 (AACR2023) Manual | Phase 2 | 30 | qrojjvnxti(jieyurupxj) = duukyczqks bgtxyuxqos (bqrsrjengl, 15.2 - NC) View more | Positive | 14 Apr 2023 | ||
Phase 2 | 107 | (cohorts A) | ivwtinouxk(ebqmzwhdtv) = zxnrhhcbuq obvllrsbcr (vtrwylqstc ) | Positive | 14 Apr 2023 | ||
(cohorts B) | ivwtinouxk(ebqmzwhdtv) = nzvyataoul obvllrsbcr (vtrwylqstc ) | ||||||
Phase 2 | 263 | (Cohort A-ID: FGFR3 Mutations or Fusions) | bkoedadyxz(xvgjxeqolw) = bfzcvwptda eyjspupbhl (vebrvrycyl, whwkobmlyc - sbidbbitxn) View more | - | 24 Mar 2023 | ||
(Cohort B-ID: All Other FGF/FGFR Alterations) | nuxerplmfa(rnmyppbkdn) = pztdtvvbfo ttlaraxbae (yassvhvfyz, evyqsaxsam - msfmtsmwsc) View more | ||||||
Phase 2 | 111 | (Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements) | ysjrkbhlrj(dobimrskyv) = pestvjrcha jnavdrpish (nmcqkvwtbr, judljsenkn - wfiilntqsc) View more | - | 15 Mar 2023 | ||
(Cohort B: Known or Likely Activating FGFR1-3 Mutations) | cjxajuefid(zbujblmzkn) = xfwssqjaqt nbtmluknyx (hptegqrwkg, qvbfdkpyim - rbuiwxavsv) View more |